Search clinical trials for: Lemborexant-matched placebo.

Total 53868 results

Eisai Inc.
Purdue Pharma LP

Completed

Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia

Irregular Sleep-Wake Rhythm Disorder

United States, Japan, United Kingdom
Eisai Inc.

Completed

Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1) (SUNRISE 1)

Insomnia

United States, Spain, United Kingdom, Italy, Germany, France, Canada
Eisai Inc.

Completed

Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder

Insomnia Disorder

United States
Cedars-Sinai Medical Center

Completed

Personalized Cancer Care at Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute

Cancer

United States
Gateway Institute for Brain Research

Recruiting

Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease (NOSE-PD)

Parkinson Disease

United States
Eisai Inc.
Purdue Pharma LP

Completed

Study to Evaluate the Effect of Lemborexant Versus Placebo on Driving Performance in Healthy Adult and Elderly Subjects

Healthy Participants

Netherlands
Washington University School of Medicine

Recruiting

DORA and LP in Alzheimer's Disease Biomarkers

Alzheimer Disease

United States
GlaxoSmithKline

Completed

Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular Dystrophy

Muscular Dystrophies

Germany, Belgium, Turkey, Netherlands, Spain, Israel, Australia, France, United Kingdom
Ore Pharmaceuticals, Inc.

Unknown

Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis

Mild to Moderate Ulcerative Colitis

Canada, India
Montefiore Medical Center
United States Department of Defense; Jazz Pharmaceuticals

Recruiting

Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)

Autism Spectrum Disorder

United States
Takeda

Terminated

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants

Pharmacokinetics | Pharmacodynamics | Tolerability | Safety

United States
Pfizer

Terminated

A Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers

Sleep | Healthy Volunteers

United States
E-Star BioTech, LLC
Mayo Clinic; PPD

Not yet recruiting

To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension

Difficult to Control Hypertension
Eisai Inc.

Completed

A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants

Healthy Volunteers

United States
Eisai Inc.

Completed

A Study to Assess the Safety and Tolerability of E2730 After Multiple Dose and the Food Effect After Single Dose in Healthy Participants

Healthy Volunteers

United States
Eisai Inc.

Completed

A Study to Assess the Safety and Tolerability of E2511 in Healthy Participants

Healthy Volunteers

United States
Pfizer

Completed

Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers

Healthy | Sleep

United States
Eisai Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy Subjects

Healthy Subjects

United States
Bristol-Myers Squibb

Completed

To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants

Thrombosis

United States
Moleac Pte Ltd.

Completed

Study of NeuroAid In Enhancing Recovery After Stroke (TIERS)

Stroke | Cerebral Infarction

Singapore
Ipsen

Recruiting

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis (ELFIDENCE)

Primary Biliary Cholangitis (PBC)

United States, Spain, Romania
EMD Serono
Merck KGaA, Darmstadt, Germany

Terminated

Atacicept in Subjects With Optic Neuritis

Optic Neuritis

United States, France, Spain, United Kingdom, Canada, Germany, Czech Republic, Belgium, Australia, Switzerland, Lebanon
Florida State University

Completed

Nighttime Feeding and Morning Endurance Performance

Poor Performance Status

United States
Navitor Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc.

Recruiting

Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression

Treatment Resistant Depression

United States
Destiny Pharma Plc

Completed

Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection

Staphylococcal Infections | Surgical Site Infection

United States, Serbia, Georgia
National University Hospital, Singapore

Completed

NEURoaid II (MLC 901) Assessment in Cognitively Impaired Not Demented Subjects (NEURITES)

Cognitive Impairment

Singapore, Philippines, Vietnam
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I) (AUGUST I)

Rheumatoid Arthritis

United States, Canada
Kurume University
Eisai Inc.; Mebix Inc

Completed

An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Transitioning to Lemborexant in Japanese Subjects With Insomnia

Insomnia

Japan
Eisai Inc.

Completed

A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006

Insomnia

United States
Indiana University School of Medicine

Completed

A Pilot Study of Fish Oil Supplementation in Hemodialysis Patients

End-Stage Renal Disease Patients on Hemodialysis

United States
Agios Pharmaceuticals, Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

Healthy Volunteers | Anemia, Sickle Cell

United States, Spain, Denmark
Sprim Advanced Life Sciences
Cerebos

Completed

Effects of Essence of Chicken on Physical Fatigue, Working Memory and Attention

Fatigue | Healthy Subjects
Ipsen

Recruiting

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. (ELMWOOD)

Primary Sclerosing Cholangitis

United States, Spain, Germany, Canada, United Kingdom, Italy, Portugal
GlaxoSmithKline

Completed

GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults

Sepsis

United States, Canada, France, Netherlands, Russian Federation, Taiwan, Czechia, Estonia, Spain, Sweden, Thailand, Germany, Belgium, Israel, United Kingdom, Korea, Republic of, Portugal, Finland, Latvia, New Zealand, Malaysia, South... and more
Eisai Inc.
Purdue Pharma LP

Completed

A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users

Insomnia Disorders

Canada
University of Virginia
National Institutes of Health (NIH)

Completed

Zibotentan, an Endothelin Receptor Antagonist, Patients With Intermittent Claudication

Peripheral Arterial Disease | Intermittent Claudication

United States
Eisai Inc.
Purdue Pharma LP

Completed

Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea

Obstructive Sleep Apnea | Healthy Subjects

United States
Eisai Co., Ltd.

Completed

A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout

Gout

China
Wuhan Createrna Science and Technology Co., Ltd

Completed

A Study of Multiple Ascending Doses MY008211A in Healthy Adults

Paroxysmal Nocturnal Hemoglobinuria

China
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis (FENtrepid)

Multiple Sclerosis, Primary Progressive

United States, Canada, Australia, United Kingdom, Hungary, Bulgaria, Puerto Rico, Poland, Argentina, Brazil, Germany, Greece, Italy, Peru, Portugal, Russian Federation, Spain, Turkey, Ukraine, Israel, France, Switzerland, Colombia, Me... and more
Chulalongkorn University

Recruiting

Effects of Lemborexant as a Treatment for Moderate-to-severe OSA Patients With Low Arousal Threshold (LOSALAT)

OSA

Thailand
Eisai Inc.

Completed

Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)

Insomnia Disorder

United States, Canada, Finland, Germany, Italy, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Romania, Spain
Taisho Pharmaceutical Co., Ltd.

Completed

Early Phase 2 Clinical Study of TS-142 in Patients With Insomnia Disorder

Insomnia Disorder

Japan
Merck Sharp & Dohme LLC

Completed

Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)

Primary Insomnia
Hansoh BioMedical R&D Company

Recruiting

Study of HS-10384 in Participants of Chinese Postmenopausal Women

Vasomotor Symptoms

China
Taisho Pharmaceutical Co., Ltd.

Completed

A Clinical Pharmacology Study of TS-142 in Patients With Obstructive Sleep Apnea Hypopnea.

Patients With Mild Obstructive Sleep Apnea Hypopnea

Japan
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects

Psoriasis

China
Charsire Biotechnology Corp.

Completed

A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia

Alzheimer's Disease or Vascular Dementia

United States
Eisai Inc.

Completed

A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease

Sleep Apnea, Obstructive | Respiration Disorders | Pulmonary Disease, Chronic Obstructive

United States
HVMN Inc
Florida Institute for Human and Machine Cognition

Unknown

Ketone Esters for Optimization of Cognitive Performance in Hypoxia

Hypoxia | Ketosis

3

Subscribe